A plant stanol yogurt drink alone or combined with a low-dose statin lowers serum triacylglycerol and non-HDL cholesterol in metabolic syndrome patients

Journal of Nutrition

Volumn 139, Issue 6, 2009, Pages 1143-1149

  Plat, Jogchum ^a   Brufau, Gemma ^a   Dallinga Thie, Geesje M ^b   Dasselaar, Margreet ^a   Mensink, Ronald P ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; BIOLOGICAL MARKER; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; FATTY ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN; STANOL ESTER; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; FATTY ACID BLOOD LEVEL; FEMALE; FOOD INTAKE; HUMAN; HUMAN CELL; INFLAMMATION; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; LOW DRUG DOSE; MALE; METABOLIC SYNDROME X; MONOTHERAPY; PROTEIN CONTENT; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL;

APOLIPOPROTEINS; BEVERAGES; BODY WEIGHT; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; DNA-BINDING PROTEINS; DRUG THERAPY, COMBINATION; FATTY ACIDS, NONESTERIFIED; GENE EXPRESSION REGULATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; METABOLIC SYNDROME X; PPAR ALPHA; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIMVASTATIN; SITOSTEROLS; TRIGLYCERIDES; YOGURT;

EID: 66749118878     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.3945/jn.108.103481     Document Type: Article

References (28)

1. Grundy SM. United States Cholesterol Guidelines 2001: expanded scope of intensive low-density lipoprotein-lowering therapy. Am J Cardiol. 2001;88:J23-7.
2. Deedwania PC, Hunninghake DB, Bays HE, Jones PH, Cain VA, Blasetto JW, for the STELLAR Study. Group effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. Am J Cardiol. 2005;95:360-366 (Pubitemid 40164540)
3. Musial J, Undas A, Gajewski P, Jankowski M, Sydor W, Szczeklik A. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int J Cardiol. 2001;77:247-253 (Pubitemid 32155911)
4. Naumann E, Plat J, Kester ADM, Mensink RP. The baseline serum lipoprotein profile is related to plant stanol induced changes in seum lipids and lipoproteins. J Am Coll Nutr. 2008;27:117-126.
5. De Jong A, Plat J, Bast A, Godschalk RWL, Basu S, Mensink RP. Effects of plant sterol and stanol ester consumption on lipid metabolism, antioxidant status and markers of oxidative stress, endothelial function and low-grade inflammation in patients on current statin treatment. Eur J Clin Nutr. 2008;62:263-273
6. Devaraj S, Autret BC, Jialal I. Reduced-calorie orange juice beverage with plant sterols lowers C-reactive protein concentrations and improves the lipid profile in human volunteers. Am J Clin Nutr. 2006;84:756-761 (Pubitemid 44715657)
7. Plat J, Mensink RP. Vegetable oil based versus wood based stanol ester mixtures: effects on serum lipids and hemostatic factors in non hypercholesterolemic subjects. Athersoclerosis. 2000;148:101-112
8. Niemeijer-Kanters SDJM, Dallinga-Thie GM, Ruijter-Heijstek FC, Algra A, Erkelens DW, Banga JD, Jansen H. Effect of intensive lipid-lowering strategy on low-density lipoprotein particle size in patients with type 2 diabetes mellitus. Atherosclerosis. 2001;156:209-216 (Pubitemid 32429614)
9. Leeuwenberg JFM, Smeets EF, Neefjes JJ, Shaffer MA, Cinek T, Jeunhomme GMAA, Ahern TJ, Buurman WA. E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology. 1992;77:543-549 (Pubitemid 23000475)
10. Bouma MG, Laan MP, Dentener MA, BuurmanWA. Analysis of soluble adhesion molecules. In: Immunochemistry 2: a practical approach. Oxford: Oxford University Press; 1997.
11. DeLanghe JR, Langlois MR, de Bacguer D, Mak R, Capel P, van Renterghem L, de Backer G. Discriminative value of serum amyloid A and other acute-phase proteins for coronary heart disease. Atherosclerosis. 2002;160:471-476 (Pubitemid 34159343)
12. Katan MB, Grundy SM, Jones P, Law M, Miettinen T, Paoletti R. Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin Proc. 2003;78:965-978 (Pubitemid 36936128)
13. Homma Y, Ikeda I, Ishikawa T, Tateno M, Sugano M, Nakamura H. Decrease in plasma low-density lipoprotein cholesterol, apolipoprotein B, cholesteryl ester transfer protein, and oxidized low-density lipoprotein by plant stanol ester-containing spread: a randomized, placebo-controlled trial. Nutrition. 2003;19:369-374 (Pubitemid 36390134)
14. Lottenberg AM, Nunes VS, Nakandakare ER, Neves M, Bernik M, Lagrost L, dos Santos JE, Quintao E. The human cholesteryl ester transfer protein I405V polymorphism is associated with plasma cholesterol concentration and its reduction by dietary phytosterol esters. J Nutr. 2003;133:1800-1805 (Pubitemid 36666516)
15. Ikeda I, Konno R, Shimizu T, Ide T, Takahashi N, Kawada T, Nagao K, Inoue N, Yanagita T, et al. Campest-5-en-3-one, an oxidized derivative of campesterol, activates PPARalpha, promotes energy consumption and reduces visceral fat deposition in rats. Biochim Biophys Acta. 2006;1760:800-807. (Pubitemid 44419349)
16. Baba MI, Kaul D, Grover A. Imortance of blood cellular genomic profile in coronary heart disease. J Biomed Sci. 2006;13:17-26. (Pubitemid 43162502)
17. Myerson M, Ngai C, Jones J, Holleran S, Ramakrishnan R, Berglund L, Ginsberg HN. Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia. J Lipid Res. 2005;46:2735-2744 (Pubitemid 43107486)
18. Bilz S, Wagner S, Schmitz M, Bedynek A, Keller U, Demant T. Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia. J Lipid Res. 2004;45:174-185 (Pubitemid 38176628)
19. Li JJ, Chen MZ, Chen X, Fang CH. Rapid effects of simvastatin on lipid profile and C-reactive protein in patients with hypercholesterolemia. Clin Cardiol. 2003;26:472-476 (Pubitemid 37221626)
20. Gylling H, Hallikainen M, Kolehmainen M, Toppinen L, Pihlajamäki J, Mykkänen H, Agren JJ, Rauramaa R, Laakso M, et al. Cholesterol synthesis prevails over absorption in metabolic syndrome. Transl Res. 2007;149:310-316 (Pubitemid 46818162)
21. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843 (Pubitemid 30165206)
22. Cater NB, Garcia-Garcia A, Vega GL, Grundy SM. Responsiveness of plasma lipids and lipoproteins to plant stanol esters. Am J Cardiol. 2005;96 Suppl:D23-8. (Pubitemid 40898166)
23. AbuMweis SS, Vanstone CA, Ebine N, Kassis A, Ausman LM, Jones PJH, Lichtenstein AH. Intake of a single morning dose of standard and novel plant sterol preparations for 4 weeks does not dramatically affect plasma lipid concentrations in humans. J Nutr. 2006;136:1012-1016
24. Acuff RV, Cai DJ, Dong Z, Bell D. The lipid lowering effect of plant sterol ester capsules in hypercholesterolemic subjects. Lipids Health Dis. 2007;6:11. (Pubitemid 46626115)
25. Sager PT, Melani L, Lipka L, Strony J, Yang B, Ramachandran S, Veltri E. Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol. 2003;92:1414-1418 (Pubitemid 37532562)
26. Sager PT, Capece R, Lipka L, Strony J, Yang B, Ramachandran S, Mitchel Y, Veltri E. Effect of ezetimibe coadministrered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. Atherosclerosis. 2005;179:361-367 (Pubitemid 40364632)
27. Bays HE, Stein EA, Shah AK, Maccubbin DL, Mitchel YB, Mercuri M. Effects of simvastatin on C-Reactive protein in mixed hyperlipidemia and hypertriglyceridemic patients. Am J Cardiol. 2002;90:942-946 (Pubitemid 35232616)
28. Seljeflot I, Tonstad S, Hjermann I, Arnesen H. Reduced expression of endothelaial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease. Atherosclerosis. 2002;162:179-185 (Pubitemid 34327356)